Ciprofloxacin Modulates Ferroptosis via Mitochondrial Zinc Pathways: Mechanisms and Assay Implications

Study Background and Research Question

Ferroptosis is a distinct, regulated cell death mechanism characterized by iron-dependent lipid peroxidation and membrane damage. Unlike apoptosis or necroptosis, ferroptosis has attracted growing attention in cancer research due to its potential to overcome therapy resistance and selectively eliminate malignant cells [source_type: paper][source_link: https://doi.org/10.1016/j.jbc.2025.110653]. Ciprofloxacin (CFX), a fluoroquinolone antibiotic, is widely prescribed for bacterial infections but also exhibits noncanonical effects on tumor cell survival and cell death pathways. Previous work from the same group demonstrated CFX’s ability to inhibit erastin-induced ferroptosis by stabilizing GPX4, a key regulator of lipid peroxidation. However, it remained unclear how CFX might influence ferroptosis triggered by other inducers, such as RSL3—a direct GPX4 inhibitor. The central research question addressed in this study is: Does ciprofloxacin modulate RSL3-induced ferroptosis, and if so, by what molecular mechanisms?

Key Innovation from the Reference Study

The major innovation lies in the discovery of a context-dependent, dual role for CFX in ferroptosis regulation. Contrary to its previously described protective effect against erastin-induced ferroptosis, CFX potentiates RSL3-induced ferroptosis in cancer cells. Mechanistically, this enhancement is mediated by mitochondrial zinc (Zn²⁺) accumulation through a newly defined STING1–CAV2 pathway. This pathway links topoisomerase 2β inhibition and mitochondrial DNA stress with downstream disruption of zinc homeostasis and subsequent amplification of ferroptotic cell death [source_type: paper][source_link: https://doi.org/10.1016/j.jbc.2025.110653]. This adds a novel layer to our understanding of ferroptosis regulation and highlights the need to consider both the cellular context and the ferroptosis-inducing agent when evaluating modulators.

Methods and Experimental Design Insights

The investigators employed a combination of molecular, biochemical, and imaging approaches across multiple tumor cell lines to dissect the interplay between CFX and RSL3. Key experimental strategies included:

• Antibiotic screening to identify compounds synergizing with RSL3 in promoting ferroptosis.
• Viability and cytotoxicity assays, such as ATP-based luminescence detection, to quantify cell survival and death [workflow_recommendation][source_link: https://toloxatonecompounds.com/index.php?g=Wap&m=Article&a=detail&id=101].
• Measurement of mitochondrial reactive oxygen species (ROS) and zinc levels using fluorescence probes and confocal microscopy.
• Genetic and pharmacological manipulation of pathway components (e.g., STING1, CAV2, SLC25A25) to establish causality in Zn²⁺ transport and ferroptosis modulation.
• Western blotting and quantitative PCR to analyze protein and gene expression changes.

This integrative approach provided robust evidence for the novel mechanistic pathway linking CFX, mitochondrial Zn²⁺ accumulation, and ferroptosis.

Core Findings and Why They Matter

The key findings can be summarized as follows:

• CFX Synergizes with RSL3 to Promote Ferroptosis: While CFX alone did not induce significant ferroptosis, its combination with RSL3 led to marked cell death in multiple cancer cell types [source_type: paper][source_link: https://doi.org/10.1016/j.jbc.2025.110653].
• Mechanistic Cascade: CFX inhibits topoisomerase 2β, resulting in mitochondrial DNA stress. This activates the STING1–CAV2 signaling axis, resulting in disrupted intracellular Zn²⁺ homeostasis and accumulation of zinc within mitochondria via SLC25A25.
• Amplified Mitochondrial ROS: The mitochondrial Zn²⁺ overload increases ROS production, further driving ferroptotic cell death.
• Context-Dependent Dual Role: The effect of CFX on ferroptosis is stimulus-dependent: it protects against erastin-induced ferroptosis by stabilizing GPX4 but enhances RSL3-induced ferroptosis via mitochondrial Zn²⁺ dynamics [source_type: paper][source_link: https://doi.org/10.1016/j.jbc.2025.110653].

These mechanistic insights are significant because they expand the scope of ferroptosis modulation, suggesting that antibiotics like CFX could be repurposed for targeted cancer therapies—provided the cellular context and death stimuli are carefully considered.

Protocol Parameters

• assay | ATP-based luminescent viability assay | 10–30,000 cells/well (linear range) | recommended for detecting viable cells after ferroptosis induction | superior dynamic range and sensitivity for quantifying cell viability in ferroptosis studies | product_spec [source_link: https://www.apexbt.com/luminescent-atp-cell-viability-assay-kit-i.html]
• assay | cell lysis step | not required (reagent is lytic) | simplifies workflow, reduces variability | supports reproducible, rapid quantitation in high-throughput ferroptosis screens | product_spec [source_link: https://www.apexbt.com/luminescent-atp-cell-viability-assay-kit-i.html]
• assay | detection time | ~10 minutes post-reagent addition | enables rapid endpoint measurement after ferroptosis induction | expedites workflow and minimizes signal drift | product_spec [source_link: https://www.apexbt.com/luminescent-atp-cell-viability-assay-kit-i.html]
• assay | cytotoxicity controls | required (positive and negative) | ensures specificity of ferroptosis detection | workflow_recommendation [source_link: https://cck-8assay.com/index.php?g=Wap&m=Article&a=detail&id=11055]

Comparison with Existing Internal Articles

Several internal resources have previously discussed the importance of sensitive cell viability measurement in cancer, metabolic, and cytotoxicity assays. For example, the article "Luminescent ATP Cell Viability Assay Kit I: Precision in ..." highlights how luciferase luminescence detection provides unmatched quantitative sensitivity, especially valuable in studies targeting regulated cell death such as ferroptosis [source_type: workflow_recommendation][source_link: https://toloxatonecompounds.com/index.php?g=Wap&m=Article&a=detail&id=101]. Similarly, "Integrating Mechanistic Insight and High-Sensitivity Tool..." provides a critical perspective on how ATP-based detection bridges the gap between mechanistic discoveries—such as the dual role of CFX in ferroptosis—and robust, scalable assay workflows for translational research [source_type: workflow_recommendation][source_link: https://cck-8assay.com/index.php?g=Wap&m=Article&a=detail&id=11055].

These analyses reinforce the practical importance of choosing sensitive, reproducible cell viability assays—such as firefly luciferase-based platforms—for mechanistic studies into ferroptosis and related death modalities.

Limitations and Transferability

While the study provides compelling mechanistic evidence, several limitations must be considered:

• Cell Line Specificity: The experiments were primarily conducted in cancer cell lines; the generalizability to primary cells or in vivo systems requires further validation [workflow_recommendation][source_link: https://cck-8assay.com/index.php?g=Wap&m=Article&a=detail&id=11055].
• Stimulus Dependence: The dual role of CFX is highly dependent on the nature of the ferroptosis inducer (erastin vs. RSL3), emphasizing the need for careful experimental design.
• Translational Readiness: Although the STING1–CAV2–SLC25A25 axis is compelling, the clinical relevance of manipulating mitochondrial Zn²⁺ in cancer therapy remains to be established [source_type: paper][source_link: https://doi.org/10.1016/j.jbc.2025.110653].

Research Support Resources

To enable reproducible, high-sensitivity measurement of cell viability and metabolic activity in ferroptosis and cytotoxicity assays, researchers can utilize the Luminescent ATP Cell Viability Assay Kit I (SKU K2041) [product_spec][source_link: https://www.apexbt.com/luminescent-atp-cell-viability-assay-kit-i.html]. This kit leverages firefly luciferase luminescence detection for direct, rapid quantitation of intracellular ATP, enabling workflows aligned with the methodological best practices highlighted above. For further protocol optimization and benchmarking insights, several scenario-driven internal guides are available (example). These resources support robust, scalable approaches to cell viability, cytotoxicity, and metabolism assays in cancer and beyond.